As such, the Alliance will prioritise three main objectives for introduction and scaling up of vaccines:
The Alliance will provide support for 18 vaccines, including inactivated polio vaccine (IPV) and vaccines identified under the new Vaccine Investment Strategya (VIS; as approved by the Board in November 2018). While providing a wider range of vaccines, the Alliance will offer more flexibility to countries in vaccine introductions, and will assist countries in identifying and prioritising those vaccines that are most appropriate for their local context, capacity and disease burden.
While Gavi eligible countries have made significant progress has been made over the past years on introducing critical vaccines, a number of countries are still missing some key vaccines. The Alliance will continue its agenda of introducing and scaling up coverage of vaccines including in the most fragile countries where vaccines can have the highest impact on child mortality. The new VIS vaccines will be an opportunity to support countries in taking a life-course and integrated approach to immunisation. This would provide the opportunity for countries to roll out other health interventions that would be part of a broader primary health care (PHC) package and contribute to the journey towards universal health coverage (UHC).
Gavi strengthens outbreak preparedness and response in countries through routine immunisation support for epidemic diseases, funding of global vaccine stockpiles for outbreak response and investments in surveillance for vaccine-preventable diseases.
The Alliance will continue to ensure access to vaccines for outbreak prone diseases and to scale up vaccines for diseases prone to AMR such as the pneumococcal and Typhoid vaccines and also some of the VIS vaccines including Cholera and multivalent meningococcal vaccines.